Overall, our findings suggest a promising therapeutic avenue for HCC, highlighting the potential of arsenic sulfide combined with PD - 1 inhibitors to enhance immune-mediated tumor clearance. This evidence concerns the gene RPL17 and hepatocellular carcinoma.